119 related articles for article (PubMed ID: 20511354)
1. Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society.
Chahal M
J Med Ethics; 2010 Jun; 36(6):367-70. PubMed ID: 20511354
[TBL] [Abstract][Full Text] [Related]
2. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
Schüklenk U; Lowry C
Br Med Bull; 2009; 89():7-22. PubMed ID: 19056723
[TBL] [Abstract][Full Text] [Related]
3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
4. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
Bender S; Flicker L; Rhodes R
Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
[No Abstract] [Full Text] [Related]
5. Dilemmas in the compassionate supply of investigational cancer drugs.
Lewis JR; Lipworth W; Kerridge I; Doran E
Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
7. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
8. The proper focus for FDA regulations: why the fundamental right to self-preservation should allow terminally ill patients with no treatment options to attempt to save their lives.
Puckett A
SMU Law Rev; 2007; 60(2):635-65. PubMed ID: 17849632
[No Abstract] [Full Text] [Related]
9. Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.
Pinxten W; Nys H; Dierickx K
J Med Ethics; 2010 Dec; 36(12):791-4. PubMed ID: 20852303
[TBL] [Abstract][Full Text] [Related]
10. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
Meyers FJ; Linder J; Beckett L; Christensen S; Blais J; Gandara DR
J Pain Symptom Manage; 2004 Dec; 28(6):548-56. PubMed ID: 15589080
[TBL] [Abstract][Full Text] [Related]
12. Phase I cancer trials: limitations and implications.
Dillman RO; Koziol JA
Mol Biother; 1992 Sep; 4(3):117-21. PubMed ID: 1445664
[TBL] [Abstract][Full Text] [Related]
13. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
14. Finding boundaries inside prison walls: case study of a terminally ill inmate.
O'Connor MF
Death Stud; 2004 Jan; 28(1):63-76. PubMed ID: 14969279
[TBL] [Abstract][Full Text] [Related]
15. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
16. Reimbursement for cancer treatment: coverage of off-label drug indications.
American Society of Clinical Oncology
J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
[TBL] [Abstract][Full Text] [Related]
17. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
18. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
19. Comparing antibody and small-molecule therapies for cancer.
Imai K; Takaoka A
Nat Rev Cancer; 2006 Sep; 6(9):714-27. PubMed ID: 16929325
[TBL] [Abstract][Full Text] [Related]
20. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
Fountzilas E; Said R; Tsimberidou AM
Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
